NEUROREGENERATION THERAPY MARKET ANALYSIS

Market News

Global Neuroregeneration Therapy Market- Recent Developments

Research and Development Activities

• NurOwn (BrainStorm Cell Therapeutics): NurOwn is an investigational autologous mesenchymal stem cell-based therapy for the treatment of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS). On October 24, 2023, BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced a strategic realignment to accelerate development of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS).
• Furthermore, the realignment is designed for various parameters mentioned below:
  • Support the company plans to conduct a double-blind, placebo-controlled Phase 3b U.S. clinical trial for NurOwn in ALS with an open-label extension and
  • Continue to publish data from NurOwn's Phase 3 clinical trial on: biomarkers, long-term safety and survival, and the Expanded Access Program, providing transparency around NurOwn data and progressing ALS drug development

• AAV-GAD gene therapy (MeiraGTx): MeiraGTx, a global clinical-stage gene therapy company, is developing an investigational gene therapy called AAV-GAD for the treatment of Parkinson's disease. For instance, in October 2022, MeiraGTx, LLC, a global clinical-stage gene therapy company, announced the initiation of clinical trial to study the safety and tolerability of adeno-associated virus (AAV)-mediated delivery of glutamic acid decarboxylase (GAD) gene transfer into the subthalamic nuclei (STN) of participants with Parkinson's Disease, which is currently in phase 2 of clinical trial and actively recruiting health volunteers
• On June 30, 2023, Ever Supreme Bio Technology Co., Ltd., a company that engages in the research, development, and sale of stem cell products, announced the initiation of clinical trial to study the safety and efficacy of repeat IV(Intravenous) and IT(Intrathecal) administrations of UMSC01 in patients with MS. While anti-inflammatory drugs are routinely used for the treatment of Multiple Sclerosis, which is currently in Phase 2 of clinical trial.

Collaboration and License Agreement

• Stem Pharm and Verge Genomics: On October 10, 2023, Stem Pharm Inc., a drug discovery platform company, and Verge Genomics, a biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, announced a collaboration to develop a disease model to validate novel targets identified by Verge for Parkinson’s disease (PD)
• NeuroSense and QuantalX: On February 9, 2023, NeuroSense Therapeutics Ltd., a clinical-stage drug development company, and QuantalX Neuroscience Ltd, the developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced a collaboration to improve early diagnosis and treatment of neurodegenerative diseases
• Biogen and Sage Therapeutics: In November 2020, Biogen, a pharmaceutical company, and Sage Therapeutics, a biotechnology company, announced that both companies had entered into a collaboration and license agreement to develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders. The collaboration and license agreement aims to combine Biogen's expertise in neuroscience with Sage Therapeutics' knowledge in developing therapies for CNS disorders.